Table 2. Process variables relating to ancillary diagnosis and antipsychotic pharmacotherapy (with indication of subgroup size)^*1.

	Ward A passive dissemination		Ward B active dissemination
	pre	post	pre	post
Head CT on initial presentation	100%	100%	75%	86%
	(2 pts.)	(2 pts.)	(8 pts.)	(7 pts.)
Pregnancy test for women up to age 50	33%	50%	78%	100%*2
	(6 pts.)	(8 pts.)	(9 pts.)	(8 pts.)
ECG monitoring for all	34 days	24 days	33 days	29 days
Drug monitoring on Day 35	33%	38%	15%	69%*2
Monotherapy on Day 35	71%	55%	39%	50%
Underdosing on Day 35	29%	50%	15%	7%*2
Overdosing on Day 35	0%	8%	23%	14%
Mean dose on Day 35	545 CPZ	500 CPZ	608 CPZ	594 CPZ
Mean dose for patients with initial presentation	886 CPZ*2	450 CPZ	467 CPZ	423 CPZ
	(2 pts.)	(2 pts.)	(8 pts.)	(7 pts.)

^*1he DGPPN guidelines recommend a head CT on the initial presentation of schizophrenia and regular ECG monitoring (at least at the start of treatment and 4 weeks after); according to the PORT recommendations, the daily antipsychotic dose should lie between 300 und 1000 chlorpromazine equivalents (CPZ) (or up to 500 CPZ for initial presentations).

^*2≈ statistically significant at 5%.